New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out
Loading...
Shape
NKGen Biotech, Inc. Common Stock
NKGN
Shape
US Flag

NASDAQ

Unprofitable

Unprofitable

13M

Biotechnology

Next Earning date - 12 Nov 2024

13M

Biotechnology

Next Earning date - 12 Nov 2024

0.37USD
Shape-0.01 ( -2.37%)
favorite-chart

Relative Strenght

favorite-chart

Volume Buzz

-82%
favorite-chart

Earning Acce

No
favorite-chart

Dist 52w H.

93%
OverviewChart

Quote Panel

Shape
Updated October 3, 2024
1W -7.57 % 1M -49.25 % 3M -72.31 % 1Y -92.40 %

Key Metrics

Shape

  • Market Cap

    13.18M

  • Shares Outstanding

    35.52M

  • Share in Float

    11.64M

  • Dividende

    0

  • Earning Date

    12 Nov 2024

  • Price Target

    0.371

  • Average Volume

    915925

  • Beta

    0.544

  • Range

    0.362-5.21

  • Industry

    Biotechnology

  • Website

    https://www.grafacq.com

  • Sector

    Healthcare

Fundamentals

Shape

N/A

P/E Ratio

0.00x

P/S Ratio

-0.13x

P/B Ratio

-0.4

Debt/Equity

0.0%

Net Margin

$-3.4

EPS

How NKGN compares to sector?

P/E Ratio

NKGN

0x

Relative Strength

Shape

NKGN

Sector

loading...

Top 5 RS in Group

Symbol

Company

RS

5-Day Perf.

Forecast

Shape

No Data Available

Analyst rating

No Data Available

Last analyst upgrade/downgrade

No Data Available

Earnings GrowthShape

status-upYoY

Current

Estimates

Q2.22

arrow
arrow

+209%

0.22
vs -0.20

Q3.22

arrow
arrow

-81%

0.04
vs 0.22

Q4.22

arrow
arrow

N/A

-0.14
vs -0.06

Q1.23

arrow
arrow

-81%

0.02
vs 0.09

Q2.23

arrow
arrow

N/A

-0.11
vs 0.22

Q3.23

arrow
arrow

N/A

-2.48
vs 0.04

Q4.23

arrow
arrow

N/A

NA
vs -0.14

Q1.24

arrow
arrow

N/A

-0.25
vs 0.02

Q2.24

arrow
arrow

N/A

-0.67
vs -0.11

Q3.24

arrow
arrow

+162%

1.54
vs -2.48

Sales GrowthShape

status-upYoY

Current

Estimates

Q1.22

arrow
arrow

NA

NA  vs NA

Q2.22

arrow
arrow

NA

NA  vs NA

Q3.22

arrow
arrow

NA

3K  vs NA

Q4.22

arrow
arrow

NA

NA  vs NA

Q1.23

arrow
arrow

NA

NA  vs NA

Q2.23

arrow
arrow

NA

NA  vs NA

Q3.23

arrow
arrow

-100%

NA  vs 3K

Q4.23

arrow
arrow

NA

NA  vs NA

Q1.24

arrow
arrow

NA

NA  vs NA

Q2.24

arrow
arrow

NA

NA  vs NA

Return on EquityShape

status-upQoQ

Q3.22

arrow
arrow

+1%

0.01
vs 0.03

Q4.22

arrow
arrow

-2%

-0.02
vs 0.01

Q1.23

arrow
arrow

+0%

0
vs -0.02

Q2.23

arrow
arrow

-3%

-0.03
vs 0

Q3.23

arrow
arrow

+82%

0.82
vs -0.03

Q4.23

arrow
arrow

+83%

0.83
vs 0.82

Q1.24

arrow
arrow

+12%

0.12
vs 0.83

Q2.24

arrow
arrow

+23%

0.23
vs 0.12

Institutionnal OwnershipShape

status-up

Earnings Growth

Latest News

NKGN

globenewswire.com

8 hours ago

NKGen Biotech's Positive Phase 1 Clinical Data in Moderate Alzheimer's Disease Advances Troculeucel into Phase 2 with First Patient Dosed in Phase 1/2a Trial
NKGN

globenewswire.com

8 hours ago

NKGen Biotech to Present at the H.C. Wainwright 26th Annual Global Investment Conference
NKGN

globenewswire.com

8 hours ago

NKGen Biotech Presents New Positive SNK01 Biomarker Data at the 2024 Alzheimer's Association International Conference
NKGN

globenewswire.com

8 hours ago

NKGen Biotech to Present New Positive SNK01 Clinical Trial Biomarker Data at the 2024 Alzheimer's Association International Conference
NKGN

investorplace.com

11 hours ago

Why Is NKGen Biotech (NKGN) Stock Up 18% Today?
NKGN

globenewswire.com

16 hours ago

NKGen Biotech Receives Notification From Nasdaq Related to Delayed Quarterly Report

New Feature Coming Soon, Stay Tuned!

ShapeShape